Sunrest Lifescience profit attributable falls 30% in H1
Key highlights
- Consolidated total income fell 6% to Rs 31.89 crore in the half year ended September 30, 2026.
- Profit attributable to shareholders declined 30% to Rs 54.93 lakh from Rs 78.36 lakh.
- Standalone total income from operations rose 39% to Rs 19.51 crore, while standalone profit after tax fell to Rs 18.17 lakh.
- Consolidated inventories increased to Rs 24.56 crore at September 30, 2026, from Rs 17.06 crore at March 31, 2026.
powered by IRIS

Sunrest Lifescience Limited reported profit attributable to shareholders of Rs 54.93 lakh for the half year ended September 30, 2026, down 30% from Rs 78.36 lakh a year earlier, as consolidated total income declined 6% to Rs 31.89 crore from Rs 34.01 crore.
Know Sunrest Lifescience inside out
Results, valuation, peers and who's buying, in one view.
How did Sunrest Lifescience’s consolidated earnings change?
Sunrest Lifescience’s consolidated total income fell by Rs 2.12 crore to Rs 31.89 crore in the half year ended September 30, 2026, from Rs 34.01 crore in the corresponding 2025 half-year. The filing shows no separately reported other income in either of the two comparative half-year columns, leaving the stated total income aligned with income from operations.
Total expenses declined by Rs 1.32 crore to Rs 30.65 crore from Rs 31.96 crore, a smaller reduction than the decline in income. Profit before tax therefore decreased to Rs 1.24 crore from Rs 2.05 crore, while the filing records no exceptional items in either half-year.
Consolidated profit after tax was Rs 99.45 lakh, compared with Rs 1.42 crore in the prior-year half-year. Tax expense fell to Rs 30.34 lakh from Rs 62.89 lakh, including current tax of Rs 30.41 lakh and a deferred-tax credit of Rs 1.07 lakh in the latest period.
Why did Sunrest Lifescience’s attributable profit decline?
Sunrest Lifescience’s filing reports profit attributable to shareholders of Rs 54.93 lakh for the September 2026 half-year, compared with Rs 78.36 lakh in the corresponding 2025 period. The group’s reported profit after tax fell by Rs 43.02 lakh to Rs 99.45 lakh over the same comparison.
The statement separately reports minority interest’s share of profit or loss at Rs 36.52 lakh for the latest half-year and Rs 60.11 lakh a year earlier. The filing does not provide a further explanation of the movements in the shareholder-attributable and minority-interest amounts.
Basic and diluted earnings per equity share were both Rs 2.65 for the half year ended September 30, 2026, compared with Rs 4.17 for the corresponding 2025 period. The result statement also records no profit or loss from discontinued operations in either half-year.
Which cost lines changed most for Sunrest Lifescience?
Sunrest Lifescience’s cost of materials consumed declined to Rs 10.39 crore from Rs 14.76 crore, the largest reduction among the listed expense lines. Purchases of stock-in-trade moved in the opposite direction, increasing to Rs 11.51 crore from Rs 8.78 crore.
Other expenses declined to Rs 4.54 crore from Rs 6.17 crore, and employee-benefit expense decreased to Rs 3.12 crore from Rs 3.54 crore. Finance costs increased to Rs 75.45 lakh from Rs 71.85 lakh, while depreciation and amortisation expense rose to Rs 83.10 lakh from Rs 68.24 lakh.
Changes in inventories reduced expenses by Rs 45 lakh in the September 2026 half-year, compared with a Rs 2.67 crore reduction in the prior-year period. With income falling by Rs 2.12 crore and total expenses declining by Rs 1.32 crore, the gap between income and expenses narrowed to Rs 1.24 crore from Rs 2.05 crore.
Got a follow-up? Ask IRIS
How did Sunrest Lifescience’s standalone result compare?
Sunrest Lifescience’s standalone total income from operations increased 39% to Rs 19.51 crore for the half year ended September 30, 2026, from Rs 14.07 crore in the comparable 2025 period. This contrasts with the 6% decline in consolidated total income to Rs 31.89 crore.
Standalone profit before tax fell to Rs 23.30 lakh from Rs 1.50 crore, while standalone profit after tax declined to Rs 18.17 lakh from Rs 1.16 crore. The parent company’s increase in standalone operating income therefore did not translate into higher standalone profit for the period.
The filing presents the standalone and consolidated figures but does not provide a reconciliation identifying the operations behind their differing income trends. It says the group operates within a single primary business segment, so Accounting Standard 17 segment-reporting disclosures are not applicable.
What do Sunrest Lifescience’s balance sheet and cash flow show?
Sunrest Lifescience reported consolidated total assets of Rs 73.01 crore at September 30, 2026, compared with Rs 71.41 crore at March 31, 2026. Inventories increased to Rs 24.56 crore from Rs 17.06 crore, while trade receivables declined to Rs 26.01 crore from Rs 32.46 crore.
Cash and cash equivalents were Rs 2.25 crore at September 30, 2026, down from Rs 2.76 crore at March 31, 2026. Long-term borrowings decreased to Rs 9.44 crore from Rs 11.96 crore, whereas short-term borrowings increased to Rs 7.50 crore from Rs 5.50 crore.
The consolidated cash-flow statement reports net operating cash flow of Rs 4.01 crore for the period ended September 30, 2026. Investing activities used Rs 3.64 crore and financing activities used Rs 85.95 lakh, producing a net decrease in cash and cash equivalents of Rs 51.33 lakh; its comparative column is labelled period ended March 31, 2025 and shows operating cash outflow of Rs 5 lakh.
Conclusion
Sunrest Lifescience’s September 2026 half-year filing shows that lower consolidated income was accompanied by a sharper decline in pre-tax profit, consolidated profit after tax and profit attributable to shareholders. The decline in materials consumed and other expenses did not fully offset higher stock-in-trade purchases, finance costs and depreciation, while standalone income rose but standalone profit fell.
What to watch next is whether later disclosures explain the different standalone and consolidated income movements and provide further context for the reported profit allocation to minority interest. The filing contains no earnings target or operational plan, but it records inventories of Rs 24.56 crore and short-term borrowings of Rs 7.50 crore at September 30, 2026, compared with Rs 17.06 crore and Rs 5.50 crore respectively at March 31, 2026.


